For 3-6 months.Group 1 Per/Ind was initiated in newly diagnosed patients (n = 7032); in Group 2 Per/Ind replaced previous therapy in patients already treated but having either their BP still uncontrolled or experiencing side-effects (n = 7423); in Group 3 Per/Ind was added to previous treatment in patients with persistently high BP (n = 3483).Was considered normalized when 140/90 mm Hg.Multivariate analysis for predictors of BP normalization was performed.On average 62 years old and had a baseline BP of 162.Mm Hg.Treatment with Per/Ind, BP normalization was reached in 69.In the Initiation group, 67.The Replacement Group, and 67.The Add-on Group (where patients were more frequently at risk, diabetic, or with target organ damage).Decreases in systolic BP of 22.Hg and in diastolic BP of 12.Hg were recorded.This trial was established to reflect everyday clinical practice, and a treatment strategy based on the Per/Indbination, administered as initial, replacement, or add-on therapy, led to normalization rates that were superior to those observed in Europe in routine practice.Results support recent hypertension guidelines which encourage the use ofbination therapy in the management of arterial hypertension.Indapamide, blood pressure normalization, risk factors,bination therapy.Read more Amiodarone hydrochloride(amiodarone hydrochloride) tablet [barr laboratories, inc.]
Get more Aldosterone infusion with high-nacl diet increases blood pressure in obese but not lean zucker rats
